NEW YORK (GenomeWeb News) – Vermillion reported after the close of the market Thursday that its third quarter revenues were down 2 percent year over year at $323,000 versus $330,000 in Q3 2013.

The company posted product revenue of $209,000, down 3 percent from $216,000 in Q3 2013. That revenue was based on 4,325 OVA1 ovarian cancer tests performed in Q3 2014 versus 4,328 tests performed in the year-ago period.

License revenue was flat at $114,000.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.

Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.

Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.

In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.